BeatSoC Virtual Clinical Trial (BVCT)

BeatSoC Virtual Clinical Trial (BVCT), developed by BioinvestGPT ApS, is a patient-data-free clinical AI infrastructure that simulates the mechanistic interaction between a drug and a disease-matched virtual human body, then outputs quantified clinical effect size against named comparators — including comparators never tested head-to-head in humans — while also providing the underlying mechanistic rationale. Research use only.

Quantified clinical effect size vs standard of care. BVCT makes your R&D clinically derisked before every GO/NO-GO decision.

BeatSoC Virtual Clinical Trial (BVCT) models Hazard Ratio (HR), Odds Ratio (OR) or Relative Ratio (RR) against standard of care at 0.1 precision (effect sizes reported to one decimal place), at every step from target ID through label expansion. Company-reported prospective accuracy: 95.6% (n=705, cohort 24 Sep 2026). Research use only.

Prospective track record

Company-reported cohort frozen 24 September 2026, counted per scored readout: accuracy 674/705 (95.6%), positive predictive value 234/261 (89.7%), negative predictive value 440/444 (99.1%); 5 predictions could not be adjudicated. Inspect every record on the prediction dashboard.

BeatSoC at every decision step.

Each pipeline gate answers one question with a modeled BeatSoC estimate: HR, OR or RR vs standard of care, at 0.1 precision.

From FIC hypothesis to BeatSoC verdict in 7 days.

A modeled GO or NO-GO with hazard ratio, odds ratio or relative risk vs standard of care, at 0.1 precision, backed by a company-reported prospective accuracy of 95.6%.

From me-better design to deal-grade BIC verdict in 7 days.

Translate differential drug designs into modeled effect-size differences in disease-matched virtual patients. Compare variants against the reference drug at 0.1 precision, with mechanistic rationales.

Why pharma can bet on this.

• Prospective track record. 705 scored readouts from 692 predictions of then-ongoing trials, each prediction timestamp-audited to predate its readout (PandaDoc e-signature audit trail).
• 0.1 precision on HR/OR/RR. Effect sizes reported to one decimal place (e.g. an illustrative HR 0.6), rather than qualitative labels.
• HIPAA-compliant architecture. AES-256-GCM encryption. Hash-chained audit log. Argon2id hashing. Re-auth on reload.
• Your data stays yours. No model fine-tuning on your pipeline data. On-prem available.

BVCT outputs are modelled decision-support estimates for drug R&D / asset decisions, validated against a prospective ex-ante track record (data.bioinvestgpt.com) — Research Use Only; not clinical advice, not for individual-patient diagnosis or treatment, and not a treatment recommendation.